Neuromuscular

The chief medical officer of Scholar Rock discussed topline results from the phase 2 TOPAZ study of apitegromab in patients with spinal muscular atrophy.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 2, 2021.

The manuscript was published in the May 2021 issues of BMC Pediatrics.

John Brandsema, MD, and Julie Parsons, MD, discuss the approval of nusinersen for the treatment of spinal muscular atrophy and their personal experiences regarding drug safety and administration in patients.

Expert pediatric neurologists review the importance of early recognition and referral to neurologists for the diagnosis of spinal muscular atrophy and when it’s appropriate to approach treatment.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending June 26, 2021.

We kindly ask you to share 5 minutes of your time with us in order to help us better understand how you use social media and how we can better serve you across different platforms.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 25, 2021.

Calli L. Cook, NP, DNP, nurse practitioner, Woodruff School of Nursing, Emory University, detailed her vision for creating change within the neurology field by incorporating advanced practice clinicians.

The exploratory end point of the ability to thrive in symptomatic patients was met by 30% of those in a subanalysis of STR1VE-EU, compared to none in the comparative Preclinical Neuromuscular Clinical Research study.

Julie Parsons, MD, comments on the role of primary care providers and gene testing for the early diagnosis of spinal muscular atrophy.

Identifying spinal muscular atrophy through early diagnosis using prenatal and newborn screenings is discussed.

Here's what is coming soon to NeurologyLive.

The Distinguished Professor of Neuromuscular Disease at UNC School of Medicine spoke to the results of the phase 3 ADAPT trial, and what else he’s like to see investigated with efgartigimod.

Neurology News Network for the week ending June 19, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 18, 2021.

The Distinguished Professor of Neuromuscular Disease at UNC School of Medicine discussed the findings of the ADAPT trial and the promise efgartigimod has shown to be an effective agent for generalized myasthenia gravis.

Santhera and ReveraGen announced findings of the phase 2b VISION DMD study of the investigational therapy.

ALS has only recently been associated with causative or disease-modifying mutations in 20 genes that encode proteins with diverse functions, with promising therapeutic targets including proteins in pathways that regulate protein homeostasis.

The nurse practitioner at the Woodruff School of Nursing at Emory University detailed why a cultural shift is needed to incorporate APCs into the neurology space and thus improve multidisciplinary care.

Julie Parsons, MD, discusses the importance of a multidisciplinary team approach to managing SMA in clinical practice.

John Brandsema, MD, leads the discussion on the 5 main types of spinal muscular atrophy and the evolution of disease classification.

The investigator at the Healey & AMG Center for ALS at Massachusetts General Hospital also discussed further research that needs to be done in ALS.

A pharmacokinetic/pharmacodynamic model indicated that the exposures predicted with a higher dose of nusinersen may lead to more clinically meaningful increases of at least 5 points on CHOP INTEND score.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 11, 2021.

A panel of experts considers current unmet needs in SMA by emphasizing the need for further study of combination therapy, more comprehensive newborn screening, and more effective early diagnosis and treatment.

Key opinion leader in neurology Claudia Chiriboga, MD, MPH provides insight into response to risdiplam in patients with SMA who were not naïve to treatment as studied in the JEWELFISH clinical trial.